Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mind over paralysis: Brain-Spine bridge aims to restore leg movement

NCT ID NCT06243952

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests a device that reads brain signals and sends them to the spinal cord to help people with chronic spinal cord injury move their legs. Three participants will use the system during rehabilitation to see if it is safe and can improve walking. The goal is to create a direct link between thought and movement, bypassing the injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Must provide Informed Consent as documented by signature (Appendix Informed Consent Form) prior to any study-related procedures, 2. Must be at least 18 years old and no older than 60 years old at the time of enrolment, 3. Must be suffering from non-progressive traumatic spinal cord injury, 4. Must be graded A, B, C, or D in the American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification, 5. Must have completed primary standard of care rehabilitation, 6. Must have stable medical, physical and psychological condition as considered by the investigator, 7. Must be lesioned at T10 or above, based on AIS level determination by the investigator, with preservation of conus function, 8. Must have sustained the injury at least 12 months before signing the consent form, 9. Must have residual upper limb function (capable of using a manual wheelchair), 10. Must be able to understand and interact with the study team in French or English, 11. Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments, 12. Must use safe contraception for women of childbearing capacity. Exclusion Criteria: 1. Must not be pregnant nor breast feeding, 2. Must not have the intention to become pregnant during the course of the study, 3. Must not have brain damage, 4. Must not have history of epilepsy, 5. Must not have participated in another clinical study using drugs or medical devices within the 30 days preceding and during the present study, except for VALSE study conducted at CHUV, 6. Must not have previously been injected with stem cells in the spinal cord, 7. Must not have any hematological disorders with increased risk for surgical intervention, 8. Must not require ventilator support, 9. Must not have limitation of walking function based on accompanying (Central Nervous System (CNS)) disorders (systemic malignant disorders, cardiovascular disorders restricting physical training, peripheral nerve disorders), 10. Must not suffer from spinal cord injury from other etiology than traumatic (ischemic, tumoral, autoimmune, etc.), 11. Must not display spinal stenosis or post traumatic damage at location of implantation, 12. Must not require the use of an intrathecal baclofen pump, 13. Must not be implanted with a device such as pacemakers or defibrillators, 14. Must not have any indication that would require Magnetic Resonance Imaging (MRI), 15. Must not suffer from congenital nor acquired lower limb abnormalities (affection of joints or bones). 16. Must not be the investigator himself, his/her family members, employees or other dependent persons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Paraplegia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHUV

    Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.